Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration

Moustafa M. El Khatib, Seiga Ohmine, Egon J. Jacobus, Jason M. Tonne, Salma G. Morsy, Sara J. Holditch, Claire A. Schreiber, Koji Uetsuka, Noemi Fusaki, Dennis A Wigle, Andre Terzic, Yogish C Kudva, Yasuhiro H Ikeda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Human induced pluripotent stem cells (iPSCs) and derived progeny provide invaluable regenerative platforms, yet their clinical translation has been compromised by their biosafety concern. Here, we assessed the safety of transplanting patient-derived iPSC-generated pancreatic endoderm/ progenitor cells. Transplantation of progenitors from iPSCs reprogrammed by lentiviral vectors (LV-iPSCs) led to the formation of invasive teratocarcinoma-like tumors in more than 90% of immunodeficient mice. Moreover, removal of primary tumors from LV-iPSC progeny-transplanted hosts generated secondary and metastatic tumors. Combined transgene-free (TGF) reprogramming and elimination of residual pluripotent cells by enzymatic dissociation ensured tumor-free transplantation, ultimately enabling regeneration of type 1 diabetes-specific human islet structures in vivo. The incidence of tumor formation in TGF-iPSCs was titratable, depending on the oncogenic load, with reintegration of the cMYC expressing vector abolishing tumor-free transplantation. Thus, transgenefree cMYC-independent reprogramming and elimination of residual pluripotent cells are mandatory steps in achieving transplantation of iPSC progeny for customized and safe islet regeneration in vivo.

Original languageEnglish (US)
Pages (from-to)694-702
Number of pages9
JournalStem cells translational medicine
Volume5
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Induced Pluripotent Stem Cells
Regeneration
Transplantation
Neoplasms
Transgenes
Teratocarcinoma
Endoderm
Patient Safety
Type 1 Diabetes Mellitus
Stem Cells
Incidence

Keywords

  • Insertional mutagenesis
  • Integration
  • iPS cells
  • Teratoma
  • Type 1 diabetes

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

El Khatib, M. M., Ohmine, S., Jacobus, E. J., Tonne, J. M., Morsy, S. G., Holditch, S. J., ... Ikeda, Y. H. (2016). Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration. Stem cells translational medicine, 5(5), 694-702. https://doi.org/10.5966/sctm.2015-0017

Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration. / El Khatib, Moustafa M.; Ohmine, Seiga; Jacobus, Egon J.; Tonne, Jason M.; Morsy, Salma G.; Holditch, Sara J.; Schreiber, Claire A.; Uetsuka, Koji; Fusaki, Noemi; Wigle, Dennis A; Terzic, Andre; Kudva, Yogish C; Ikeda, Yasuhiro H.

In: Stem cells translational medicine, Vol. 5, No. 5, 2016, p. 694-702.

Research output: Contribution to journalArticle

El Khatib, MM, Ohmine, S, Jacobus, EJ, Tonne, JM, Morsy, SG, Holditch, SJ, Schreiber, CA, Uetsuka, K, Fusaki, N, Wigle, DA, Terzic, A, Kudva, YC & Ikeda, YH 2016, 'Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration', Stem cells translational medicine, vol. 5, no. 5, pp. 694-702. https://doi.org/10.5966/sctm.2015-0017
El Khatib, Moustafa M. ; Ohmine, Seiga ; Jacobus, Egon J. ; Tonne, Jason M. ; Morsy, Salma G. ; Holditch, Sara J. ; Schreiber, Claire A. ; Uetsuka, Koji ; Fusaki, Noemi ; Wigle, Dennis A ; Terzic, Andre ; Kudva, Yogish C ; Ikeda, Yasuhiro H. / Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration. In: Stem cells translational medicine. 2016 ; Vol. 5, No. 5. pp. 694-702.
@article{ea66ca6f255e412db456f344d3c2c0e9,
title = "Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration",
abstract = "Human induced pluripotent stem cells (iPSCs) and derived progeny provide invaluable regenerative platforms, yet their clinical translation has been compromised by their biosafety concern. Here, we assessed the safety of transplanting patient-derived iPSC-generated pancreatic endoderm/ progenitor cells. Transplantation of progenitors from iPSCs reprogrammed by lentiviral vectors (LV-iPSCs) led to the formation of invasive teratocarcinoma-like tumors in more than 90{\%} of immunodeficient mice. Moreover, removal of primary tumors from LV-iPSC progeny-transplanted hosts generated secondary and metastatic tumors. Combined transgene-free (TGF) reprogramming and elimination of residual pluripotent cells by enzymatic dissociation ensured tumor-free transplantation, ultimately enabling regeneration of type 1 diabetes-specific human islet structures in vivo. The incidence of tumor formation in TGF-iPSCs was titratable, depending on the oncogenic load, with reintegration of the cMYC expressing vector abolishing tumor-free transplantation. Thus, transgenefree cMYC-independent reprogramming and elimination of residual pluripotent cells are mandatory steps in achieving transplantation of iPSC progeny for customized and safe islet regeneration in vivo.",
keywords = "Insertional mutagenesis, Integration, iPS cells, Teratoma, Type 1 diabetes",
author = "{El Khatib}, {Moustafa M.} and Seiga Ohmine and Jacobus, {Egon J.} and Tonne, {Jason M.} and Morsy, {Salma G.} and Holditch, {Sara J.} and Schreiber, {Claire A.} and Koji Uetsuka and Noemi Fusaki and Wigle, {Dennis A} and Andre Terzic and Kudva, {Yogish C} and Ikeda, {Yasuhiro H}",
year = "2016",
doi = "10.5966/sctm.2015-0017",
language = "English (US)",
volume = "5",
pages = "694--702",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Tumor-free transplantation of Patient-Derived induced pluripotent stem cell progeny for customized islet regeneration

AU - El Khatib, Moustafa M.

AU - Ohmine, Seiga

AU - Jacobus, Egon J.

AU - Tonne, Jason M.

AU - Morsy, Salma G.

AU - Holditch, Sara J.

AU - Schreiber, Claire A.

AU - Uetsuka, Koji

AU - Fusaki, Noemi

AU - Wigle, Dennis A

AU - Terzic, Andre

AU - Kudva, Yogish C

AU - Ikeda, Yasuhiro H

PY - 2016

Y1 - 2016

N2 - Human induced pluripotent stem cells (iPSCs) and derived progeny provide invaluable regenerative platforms, yet their clinical translation has been compromised by their biosafety concern. Here, we assessed the safety of transplanting patient-derived iPSC-generated pancreatic endoderm/ progenitor cells. Transplantation of progenitors from iPSCs reprogrammed by lentiviral vectors (LV-iPSCs) led to the formation of invasive teratocarcinoma-like tumors in more than 90% of immunodeficient mice. Moreover, removal of primary tumors from LV-iPSC progeny-transplanted hosts generated secondary and metastatic tumors. Combined transgene-free (TGF) reprogramming and elimination of residual pluripotent cells by enzymatic dissociation ensured tumor-free transplantation, ultimately enabling regeneration of type 1 diabetes-specific human islet structures in vivo. The incidence of tumor formation in TGF-iPSCs was titratable, depending on the oncogenic load, with reintegration of the cMYC expressing vector abolishing tumor-free transplantation. Thus, transgenefree cMYC-independent reprogramming and elimination of residual pluripotent cells are mandatory steps in achieving transplantation of iPSC progeny for customized and safe islet regeneration in vivo.

AB - Human induced pluripotent stem cells (iPSCs) and derived progeny provide invaluable regenerative platforms, yet their clinical translation has been compromised by their biosafety concern. Here, we assessed the safety of transplanting patient-derived iPSC-generated pancreatic endoderm/ progenitor cells. Transplantation of progenitors from iPSCs reprogrammed by lentiviral vectors (LV-iPSCs) led to the formation of invasive teratocarcinoma-like tumors in more than 90% of immunodeficient mice. Moreover, removal of primary tumors from LV-iPSC progeny-transplanted hosts generated secondary and metastatic tumors. Combined transgene-free (TGF) reprogramming and elimination of residual pluripotent cells by enzymatic dissociation ensured tumor-free transplantation, ultimately enabling regeneration of type 1 diabetes-specific human islet structures in vivo. The incidence of tumor formation in TGF-iPSCs was titratable, depending on the oncogenic load, with reintegration of the cMYC expressing vector abolishing tumor-free transplantation. Thus, transgenefree cMYC-independent reprogramming and elimination of residual pluripotent cells are mandatory steps in achieving transplantation of iPSC progeny for customized and safe islet regeneration in vivo.

KW - Insertional mutagenesis

KW - Integration

KW - iPS cells

KW - Teratoma

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84964277366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964277366&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0017

DO - 10.5966/sctm.2015-0017

M3 - Article

C2 - 26987352

AN - SCOPUS:84964277366

VL - 5

SP - 694

EP - 702

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 5

ER -